The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy

Author(s): Zofia Blach-Olszewska, Ewa Zaczynska, Kasia Gustaw-Rothenberg, Marco Avila-Rodrigues, George E. Barreto, Jerzy Leszek, Gjumrakch Aliev

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 25 , 2015

Become EABM
Become Reviewer
Call for Editor


The genetic, cellular, and molecular changes associated with Alzheimer disease provide evidence of immune and inflammatory processes involvement in its pathogenesis. These are supported by epidemiological studies, which show some benefit of long-term use of NSAID. The hypothesis that AD is in fact an immunologically mediated and even inflammatory pathological process may be in fact scientifically intriguing. There are several obstacles that suggest the need for more complex view, in the process of targeting inflammation and immunity in AD. In our previous studies we proposed a reliable methodology to assess innate immunity in Alzheimer patients and controls. The methodology is based on the phenomenon of human leukocytes being resistant to viral infection. The unspecific character of the resistance, dependent on interferons and tumor necrosis factor, and occurrence in cells ex vivo indicate that an in vivo mechanism of innate immunity may be involved. The above mentioned resistance could be estimated in a test based on peripheral blood leukocytes infection by vesicular stomachs virus.

Keywords: Alzheimer disease, human peripheral blood leukocytes, innate immunity, therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 17 August, 2015
Page: [3582 - 3588]
Pages: 7
DOI: 10.2174/1381612821666150710144829
Price: $65

Article Metrics

PDF: 41